Stockreport

Hot Picks: Biotech rebound turns to rare disease catalysts [BNN Bloomberg (Canada)]

Viridian Therapeutics, Inc.  (VRDN) 
PDF next year as investors weigh clinical risk, regulation and capital discipline. Analysts say rare disease programs with differentiated profiles and near-term catalysts ma [Read more]